INmune Bio Inc. Common stock (INMB) — Analysis Summary
INmune Bio Inc. Common stock (INMB) has a market cap of $49.45M with year-over-year revenue growth of +257.1%. Net margin stands at -91866.0%. The stock trades at a P/E ratio of -1.2.
Key Takeaways
- Revenue changed +257.1% year-over-year
- Net margin of -91866.0%
- P/E ratio of -1.2
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, INMB posted revenue growth of +257.1% and trades at a P/E of -1.2.
INmune Bio Inc. Common stock (INMB)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -86580.0% — severe operating losses
Net margin at -83202.0% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
21
Headquarters
BOCA RATON, FL
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.